This is, IMO, more of an issue for subsequent generations of HCV drugs—i.e. drugs not yet in clinical development. For the HCV drugs discussed on this board and the ones listed in #msg-28837898, the patent lives will run out before the “reservoir inflow” slows to an appreciable degree.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.